Showing 4501-4510 of 10192 results for "".
- Leo Pharma’s Tralokinumab Produces Sustained Improvement in ADhttps://practicaldermatology.com/news/leo-pharmas-tralokinumab-produces-sustained-improvement-in-ad/2460766/Leo Pharma’s tralokinumab 300 mg every other week plus optional topical corticosteroids (TCS) showed long-term improvements in itch, sleep, and in atopic dermatitis signs and symptoms, according to an interim analysis at 56 weeks in the ECZTEND trial that was presented at the AAD
- Promising Phase 3 Data for Oral Deucravacitinib from Bristol Myers Squibb in Psoriasishttps://practicaldermatology.com/news/promising-phase-3-data-for-oral-deucravacitinib-from-bristol-myers-squibb-in-psoriasis/2460765/In two pivotal Phase 3 trials evaluating deucravacitinib 6mg once daily for the treatment of patients with moderate to severe plaque psoriasis, significantly more patients met both co-primary endpoints—Psoriasis Area and Severity Index (PASI) 75 response and a static Physician's Global
- Phase 3 Data Show Tolerability, Efficacy for Brickell's Sofpironium Bromide in Hyperhidrosishttps://practicaldermatology.com/news/phase-3-data-show-tolerability-efficacy-for-brickells-sofpironium-bromide-in-hyperhidrosis/2460763/Data from the phase 3, open-label, long-term safety study of Brickell Biotech’s sofpironium bromide gel, 5% and 15%, provided clinically meaningful improvement in axillary hyperhidrosis severity as measured by the Hyperhidrosis Disease Severity Measure-
- Qwo Performs Well in Two Phase 3 Studies of Cellulite on the Buttockshttps://practicaldermatology.com/news/qwo-performs-well-in-two-phase-3-studies-of-cellulite-on-the-buttocks/2460747/Endo’s Qwo provides a clinically meaningful improvement in the appearance of moderate to severe cellulite in the buttocks of adult women, when compared to placebo, according to Phase 3 data. "The data, from the largest cellulite studies ever conducted, provides further eviden
- Fat Grafting Shows Promise for Cancer Patients with Radiation-induced Skin Injuryhttps://practicaldermatology.com/news/fat-grafting-shows-promise-for-cancer-patients-with-radiation-induced-skin-injury/2460730/As cancer survival rates improve, more people are living with the aftereffects of cancer treatment including chronic radiation-induced skin injury. Fat grafting procedures may unleash the healing and regenerative power of the body's natural adipose stem cells (ASCs). "Prelimina
- Sincerus Completes Financing With SWK To Support Demand For Customized Dermatologic Medicineshttps://practicaldermatology.com/news/sincerus-completes-financing-with-swk-to-support-demand-for-customized-dermatologic-medicines/2460727/Sincerus Pharmaceuticals, the parent company of Prescriber's Choice and Sincerus Florida, completed a major new round of growth financing with SWK Holdings Corporation, representing the largest investment into the company to date. Use of proceeds will include the build-out and expansion of a
- Study: Clear Masks Improve Communication with Patientshttps://practicaldermatology.com/news/study-clear-masks-improve-communication-with-patients/2460716/Seeing really is believing. New research shows that doctors who wear transparent face masks greatly improve communication with patients compared to doctors whose faces are blocked by a standard face masks. What’s more, providers who wore the ClearMask are also perc
- New from Solta: Meet the Next Generation Clear + Brilliant Laserhttps://practicaldermatology.com/news/new-from-solta-meet-the-next-generation-clear-brilliant-laser/2460711/Solta Medical is launching Clear + Brilliant Touch laser, the company’s next generation Clear + Brilliant laser. By seamlessly switching between two wavelengths with the Original and Perméa handpieces, physicians can now more easily deliver a
- Galderma and Aklief Unveil "Me Being Me" Campaign, Survey Results on Acne Zoom Burdenhttps://practicaldermatology.com/news/galderma-and-aklief-unveil-me-being-me-campaign-survey-results-on-acne-zoom-burden/2460703/Galderma Laboratories, L.P. and Aklief (trifarotene) Cream, 0.005% are launching Me Being Me, a new consumer campaign that was crafted in response to today’s increasingly digital-focused world. The campaign is designed to inspire those living with acne to feel confident
- Five-Year Data for Ilumya Show Long-term Efficacy, Safetyhttps://practicaldermatology.com/news/five-year-data-for-ilumya-show-long-term-efficacy-safety/2460698/Long-term data from Phase 3 extension trials for Sun Pharma’s Ilumya (tildrakizumab) in psoriasis show the treatment provided sustained disease control over five years among subjects who were week 28 tildrakizumab responders and etanercept partial responders/nonresponders.